Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma

Bednaruk-Młyński, E.; Pieńkowska, Joanna; Skórzak, Adam; Małkowski, Bogdan; Kulikowski, Waldemar; Subocz, Edyta; Dzietczenia, Justyna; Zalewska, Marta; Leśniewski-Kmak, Krzysztof; Zaucha, Renata; Wróbel, Tomasz; Zaucha, Jan Maciej

doi:10.3109/10428194.2014.919635

Cited by 31 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic chemotherapy might have resulted in improved survival times in these patients but it was declined by the owners. In human medicine, FDG PET/CT is already widely used as a non-invasive method for staging and control of response to treatment in patients with Non-Hodgkin’s lymphoma [33–36]. In veterinary patients, this method proved to be highly sensitive [9,11,19].…”

Section: Discussionmentioning

confidence: 99%

Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

et al. 2015

View full text Add to dashboard Cite

Introduction2-Deoxy-2-[18F]fluoro-D-glucose PET/CT is a well-established imaging method for staging, restaging and therapy-control in human medicine. In veterinary medicine, this imaging method could prove to be an attractive and innovative alternative to conventional imaging in order to improve staging and restaging. The aim of this study was both to evaluate the effectiveness of this image-guided method in canine patients with spontaneously occurring cancer as well as to illustrate the dog as a well-suited animal model for comparative oncology.MethodsTen dogs with various malignant tumors were included in the study and underwent a whole body FDG PET/CT. One patient has a second PET-CT 5 months after the first study. Patients were diagnosed with histiocytic sarcoma (n = 1), malignant lymphoma (n = 2), mammary carcinoma (n = 4), sertoli cell tumor (n = 1), gastrointestinal stromal tumor (GIST) (n = 1) and lung tumor (n = 1). PET/CT data were analyzed with the help of a 5-point scale in consideration of the patients’ medical histories.ResultsIn seven of the ten dogs, the treatment protocol and prognosis were significantly changed due to the results of FDG PET/CT. In the patients with lymphoma (n = 2) tumor extent could be defined on PET/CT because of increased FDG uptake in multiple lymph nodes. This led to the recommendation for a therapeutic polychemotherapy as a treatment. In one of the dogs with mammary carcinoma (n = 4) and in the patient with the lung tumor (n = 1), surgery was cancelled due to the discovery of multiple metastasis. Consequently no treatment was recommended.ConclusionFDG PET/CT offers additional information in canine patients with malignant disease with a potential improvement of staging and restaging. The encouraging data of this clinical study highlights the possibility to further improve innovative diagnostic and staging methods with regard to comparative oncology. In the future, performing PET/CT not only for staging but also in therapy control could offer a significant improvement in the management of dogs with malignant tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The HUFRA test we have proposed here is not aimed at replacing this examination since, in HL, 18F-FDG-PET/CT is a gold standard in staging and evaluating the response to CTx. Taking into consideration that the result is solely based on the metabolic imaging (PET) leads to upstaging or downstaging in approximately 15-40% of patients with HL with and impacts management in about 5-15% of them [37,38], HUFRA may be a source of additional unique information [39].…”

Section: Plos Onementioning

confidence: 99%

Hounsfield units and fractal dimension (test HUFRA) for determining PET positive/negative lymph nodes in pediatric Hodgkin’s lymphoma patients

et al. 2020

View full text Add to dashboard Cite

Objectives We had developed a method that can help detect and identify lymph nodes affected by the neoplastic process. Our group evaluated the fractal dimension (FD) and X-ray attenuation (XRA) of lymph nodes in HL and compared to their metabolic activity as measured by 18F-FDG-PET examination. Methods The training set included 72 lymph nodes from 31 consecutive patients, and the tested set of 71 lymph nodes from next 19 patients. The measurement of FD of each lymph node was performed before the start of therapy using original software. X-ray attenuation (XRA) expressed in HU (Hounsfield Units) from CT scans was compared with the metabolic activity of the lymphatic nodes, measured by 18F-FDG-PET examination. Results Significant differences were observed between XRA max and FD max values in assessing the PET(+) and PET(-) nodes. All nodes were scored from 0 to 2. The HUFRA test properly qualified 95% with a score of 2 and 0 points as PET(+) or PET(-).

show abstract

“…FDG-PET positivity at the treatment completion is an adverse prognostic factor for disease-free survival [ 9 ]. Metabolic imaging with PET often leads to either upstaging or downstaging in approximately 15–40 % of patients with Hodgkin lymphoma with impact on management in about 5–15 % [ 10 , 11 ]. Several studies have established the role of interim FDG-PET in the prognosis of HL during chemotherapy.…”

Section: Pet/ct In Hodgkin’s Lymphomamentioning

confidence: 99%

Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications

et al. 2015

View full text Add to dashboard Cite

ObjectiveThe purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL). PET/CT is the imaging modality of choice in the management of Hodgkin’s lymphoma (HL). However, imaging modalities other than PET/CT such as plain radiographs, ultrasound, CT, MRI and nuclear imaging can help in various stages of clinical management of HL, including the initial workup and post-treatment surveillance. Both CT and MRI help in detecting recurrences, treatment-related pulmonary, cardiovascular and abdominal complications as well as second malignancies. Familiarity with expected post-treatment changes and complications on surveillance images can help radiologists guide patient management. The purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL).Main Messages• Surveillance of HL patients is usually performed with plain radiographs and CT.• Follow-up imaging can depict normal post-treatment changes or treatment-related complications.• Imaging is important for the timely detection of second malignancies in HL patients.

show abstract

Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma

Cited by 31 publications

References 25 publications

Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

Hounsfield units and fractal dimension (test HUFRA) for determining PET positive/negative lymph nodes in pediatric Hodgkin’s lymphoma patients

Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications

Contact Info

Product

Resources

About